CGIM
OBIO icon

Cannon Global Investment Management’s Orchestra BioMed OBIO Stock Holding History

Cannon Global Investment Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,607
Closed -$96.1K – 79
2026
Q1 		$96.1K Buy
+22,607
New +$96.2K 0.19% 81

Other funds holding OBIO

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
DSC
Daytona Street Capital Saint Louis, Missouri $137M AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MFP
Meramec Financial Planners Saint Louis, Missouri $274M AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AFG
ABLE Financial Group Scottsdale, Arizona $596M AUM 23.3% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Cannon Global Investment Management's OBIO Position: Q2 2026 in Review

Cannon Global Investment Management sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 22,607 shares — an estimated $96.1K sold.

Cannon Global Investment Management first reported a position in OBIO in Q1 2026 and held it in 1 quarter. The position peaked at $96.1K in Q1 2026. 15 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Cannon Global Investment Management reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
  • Cannon Global Investment Management sold 22,607 Orchestra BioMed shares in Q2 2026, an estimated $96.1K.
  • Cannon Global Investment Management first reported a position in Orchestra BioMed in Q1 2026 and held it in 1 quarter.
  • Cannon Global Investment Management's Orchestra BioMed position peaked at $96.1K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Cannon Global Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.